Opioid overdose is the leading cause of death for Americans 25 to 64 years of age, and
opioid use disorder affects> 2 million Americans. The epidemiology of opioid-associated out …

Numerous variations on structural motifs exist within pharmaceutical compounds that have
entered the clinic. These variations have amounted over many decades based on years of …

The increasing number of opioid users among chronic pain patients, and opioid abusers
among the general population, makes perioperative pain management challenging for …

Opioid use disorder (OUD) and its consequences are a major public health concern. The
partial agonist buprenorphine is a safe and effective treatment for OUD, but concerns about …

Introduction: Management of patients with opioid use disorder (OUD) commonly includes
opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions …

Opioid use disorder continues to be a significant source of morbidity and mortality in the
USA and the world. Pharmacologic treatment with methadone and buprenorphine has been …

Objective: Opioid use disorder (OUD) in the United States has surged, with an estimated 2.5
million needing treatment. The aim of this article is to provide a clinical overview of the key …

Background: Starting with approval for clinical use in the treatment of opioid dependence in
October 2002 by the Food and Drug Administration (FDA), buprenorphine has become an …

Objectives The objective of this study is to assess West Virginia pharmacists' stocking and
dispensing practices of opioid-related medications and to identify the educational needs …

Objective There is no consensus on the optimal perioperative management of patients on
buprenorphine (BUP) for opioid use disorder (OUD). This article will review the available …